Skip to main content
Rize RecoveryThe Newsroom
Policy & Funding· Daily Pulse

The First Cannabis-Rescheduling Comment Deadline Is Tomorrow. The Decision That Matters Lands June 29.

Schedule III for FDA-approved and state-licensed medical products is already in effect. The bigger question — what happens to the rest of cannabis — gets argued in three weeks.

ByThe Rize NewsroomMay 21, 20263 min readCannabinoids

The First Cannabis-Rescheduling Comment Deadline Is Tomorrow. The Decision That Matters Lands June 29.

The cannabis-rescheduling timeline that’s actually consequential for the recovery field has three dates and one hearing.

The dates: May 20 (tomorrow) for mailed public comment, May 24 for emailed comment, and May 28 for desired-participation filings. The hearing: June 29, when the DEA’s expedited Administrative Law Judge proceeding will consider whether broader cannabis — not just the FDA-approved and state-licensed medical products already rescheduled — should be moved from Schedule I to Schedule III. The DEA notifies selected participants on June 22. Procedural details are in the April 28 Federal Register notice.

What was already decided

DOJ’s April 23 final order — in effect now — moved two specific categories of cannabis from Schedule I to Schedule III: FDA-approved cannabis-containing drug products, and cannabis subject to a state-issued medical license. Schedule III status lifts the Internal Revenue Code §280E tax disability for qualifying medical operators — a significant business-side effect — and opens new pathways for research. Recreational cannabis remains in Schedule I.

What’s actually being argued June 29

The ALJ hearing addresses whether all cannabis should be rescheduled, regardless of whether a state medical license attaches. That is the version of rescheduling that most directly affects the recovery field, for two reasons.

First, availability follows scheduling. A broader Schedule III move would not, by itself, legalize recreational use under federal law — but it would change how cannabis is treated by employers, by insurers, and by the research community. The University of Michigan’s Institute for Healthcare Policy and Innovation and others have noted that broader rescheduling carries a “signal” effect — communicating relative-risk information that the science doesn’t fully support, given that roughly one in five people who use cannabis develop cannabis use disorder.

Second, the policy is moving while the treatment infrastructure for cannabis use disorder is still under-built. Cannabis-use-disorder rates are increasing — driven by higher-potency products and more daily-use patterns — yet evidence-based behavioral treatment (CBT, MET, and contingency management) reaches only a small fraction of people who would benefit. The June 29 hearing is the moment when public-health voices, including the addiction-medicine community, can weigh in on the gap between regulatory posture and treatment capacity.

What to do this week

If you have a stake in this — clinician, recovery community, treatment program, family member of someone with cannabis use disorder — and want to submit a comment:

A comment doesn’t have to be long. A clinical observation about cannabis-use-disorder trajectory in your practice, or a family observation about navigating the existing treatment system, is the kind of input the docket has explicitly invited and that most rulemaking proceedings end up under-represented on.

Why this matters for people in recovery

If you or someone you love is dealing with cannabis use disorder, federal scheduling is several steps removed from your day. What matters more immediately is the availability of evidence-based treatment: cognitive behavioral therapy, motivational enhancement therapy, contingency management, and structured group support. The June 29 hearing is, in the end, an argument about what kind of treatment infrastructure the federal system thinks it owes the people most likely to develop cannabis use disorder. That’s worth a comment.

For navigation in Arizona, dial 211 or use Rize Recovery’s free find-help tool. If you’re in crisis, call or text 988.

Rize Recovery is policy-aware but takes no position on the scheduling debate. We focus on getting people to the treatment that helps.

Sources Cited

  1. 01.B
    https://www.federalregister.gov/documents/2026/04/28/2026-08177/schedules-of-controlled-substances-rescheduling-of-marijuana
  2. 02.B
    https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products
  3. 03.B
    https://www.gibsondunn.com/dea-downschedules-state-medical-marijuana-to-schedule-iii-expedited-hearing-set-to-consider-broader-rescheduling/
  4. 04.B
    https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana
  5. 05.B
    https://ihpi.umich.edu/news-events/news/what-does-cannabis-rescheduling-mean-science-and-society

Filed Under

policytrends

Continue reading

More from this section

Policy & Funding

The Block Grant Consolidation's Hidden Cut Is in the Mandates, Not the Number

The Behavioral Health Innovation Block Grant consolidates three SAMHSA programs at $4.126B vs $4.6B+ previously. The dollar gap understates the policy shift: categorical mandates that pushed money toward syringe programs, workforce, and harm reduction are what actually get eliminated.

Policy & Funding

The Medicaid Work Requirements Start in 2028. For People in Active Treatment, the Clock Is Already Running.

Medicaid work requirements in the One Big Beautiful Bill take effect October 2028. For people in active SUD treatment, the documentation burden may end coverage before they finish.

Policy & Funding

Washington Buried the Science on Alcohol. Now Congress Is Making It Permanent.

A government-commissioned study found no safe level of alcohol. Washington suppressed it. This week, Congress voted to ban the research program that produced it — permanently.